Education
About Us
Working with TipRanks
Follow Us
Baxter International Inc (BAX)
:BAX
BAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.33 - $40.49
Previous CloseN/A
Volume899.70K
Average Volume (3M)7.02M
Market Cap
$11.72B
Enterprise Value$25.58B
Total Cash (Recent Filing)$2.29B
Total Debt (Recent Filing)$10.31B
Price to Earnings (P/E)136.1
Beta0.74
Next Earnings
Oct 30, 2025EPS Estimate
0.6Next Dividend Ex-Date
Aug 29, 2025Dividend Yield3.5%
Share Statistics
EPS (TTM)0.59
Shares Outstanding513,174,600
10 Day Avg. Volume12,511,875
30 Day Avg. Volume7,015,691
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.18
Enterprise Value/Revenue2.15
Enterprise Value/Gross Profit5.97
Enterprise Value/Ebitda39.54
Forecast
1Y Price Target
$29.40Price Target Upside28.72% Upside
Rating ConsensusHold
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Financial StrategyThe company is focused on de-leveraging the balance sheet to create greater financial flexibility, providing capacity for share buy-backs or acquisitions.
Operational GrowthHealthcare Systems & Technologies sales exceeded the Street's consensus estimate, showing operational growth.
Product LaunchThe ongoing US NOVUM IQ pump launch continues to drive double-digit growth for the US infusion system business.
Bears Say
Guidance And OutlookBaxter's disappointing 2Q25 performance and full-year guidance reduction suggest that achieving consistent mid-single-digit sales growth and meaningful margin expansion may take longer than expected.
Margin PerformanceSales softness, along with corresponding manufacturing inefficiencies and unfavorable product mix, caused gross margins to miss consensus and operating margins to fall below expectations.
Sales PerformanceInfusion Therapies & Technologies revenue softness drove overall 2Q25 sales underperformance, highlighting the challenges in the US market.
Baxter International News
BAX FAQ
What was Baxter International Inc’s price range in the past 12 months?
Baxter International Inc lowest stock price was $21.33 and its highest was $40.49 in the past 12 months.
What is Baxter International Inc’s market cap?
Baxter International Inc’s market cap is $11.72B.
When is Baxter International Inc’s upcoming earnings report date?
Baxter International Inc’s upcoming earnings report date is Oct 30, 2025 which is in 84 days.
How were Baxter International Inc’s earnings last quarter?
Baxter International Inc released its earnings results on Jul 31, 2025. The company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.61 by -$0.02.
Is Baxter International Inc overvalued?
According to Wall Street analysts Baxter International Inc’s price is currently Undervalued.
Does Baxter International Inc pay dividends?
Baxter International Inc pays a Quarterly dividend of $0.17 which represents an annual dividend yield of 3.5%. See more information on Baxter International Inc dividends here
What is Baxter International Inc’s EPS estimate?
Baxter International Inc’s EPS estimate is 0.6.
How many shares outstanding does Baxter International Inc have?
Baxter International Inc has 513,174,600 shares outstanding.
What happened to Baxter International Inc’s price movement after its last earnings report?
Baxter International Inc reported an EPS of $0.59 in its last earnings report, missing expectations of $0.61. Following the earnings report the stock price went down -22.424%.
Which hedge fund is a major shareholder of Baxter International Inc?
Currently, no hedge funds are holding shares in BAX
Baxter International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$29.40 (28.72% Upside)
$29.40 (28.72% Upside)
Blogger Sentiment
Bullish
BAX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.3%
Last 30 Days ▲ 13.3%
Last 30 Days ▲ 13.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.51%
12-Months-Change
Fundamentals
Return on Equity
-8.96%
Trailing 12-Months
Asset Growth
-23.33%
Trailing 12-Months
Company Description
Baxter International Inc
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
BAX Company Deck
BAX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed performance for Baxter International with growth in sales and earnings and strategic partnerships being positive aspects. However, challenges in the Infusion Therapies & Technologies segment, issues with the Novum LVP platform, and a decline in gross margins presented significant concerns.View all BAX earnings summariesBAX Net sales Breakdown
55.00% U.S.
32.31% ROW
12.69% Emerging markets
BAX Stock 12 Month Forecast
Average Price Target
$29.40
▲(28.72% Upside)
Technical Analysis
Ownership Overview
0.38% Insiders
34.55% Mutual Funds
0.56% Other Institutional Investors
39.54% Public Companies and
Individual Investors